Introduction
Neurofilament light chain (NfL) is a neuron-specific cytoskeletal protein important for cell structural stability. Damage of axons releases NfL into the interstitial fluid and increased concentrations of NfL can be detected in blood samples. Recently, increased NfL concentration has been demonstrated in a cross-sectional study performed in inherited peripheral neuropathies, and their levels correlated with the severity of nerve impairment (Sandelius et al., 2018) .
Chemotherapy Induced Peripheral Neurotoxicity (CIPN) is a potentially dose-limiting side effect of chemotherapy treatments of several common forms of cancer. Several highly active and widely used antineoplastic drugs belonging to different classes (platinum-based agents, antitubulins, proteasome inhibitors) share the common feature represented by CIPN. Although the neuronal target might be different according to the neurotoxic agent administered, the main clinical features of CIPN are those of a length dependent axonopathy (Cavaletti et al. 2015) . CIPN onset and course require close monitoring, since delayed recognition or improper management (for instance missing adequate chemotherapy schedule modification) can lead to permanent nerve damage, with severe effects of patients' quality of life. However, careful monitoring of CIPN is frequently problematic, since the scales commonly used by oncologists in daily clinical practice (e.g. National Cancer Institute Common Toxicity Criteria) are not sufficiently sensitive and reliable (Cavaletti et al., 2013) , and in most cases a formal neurological assessment is not easily available.
For these reasons, the availability of a simple, fast, effective and reliable biomarker obtained from an easy accessible biological matrix might have a large impact on the clinical management and safety of cancer patients treated with neurotoxic drugs. Moreover, this putative biomarker might be used in the context of neuroprotection clinical trials, and used as a surrogate endpoint to strengthen the validity of the results based on patient reported outcomes.
To test the possibility to use NfL as a CIPN biomarker we performed this preclinical study using a well-characterized rat model based on repeated administration of the cytostatic drug vincristine, where axonopathy and sensorimotor damage are clearly evident and measurable (VIPN).
Materials and methods
The study was approved by Animal Care and Use Committee of the University of Milano-Bicocca and adhered to all guidelines for humane treatment of laboratory animals set forth in the Guide for the Care and Adult female Wistar rats (n. 8/group, 175-200 g at the beginning of the study, Envigo, Udine, Italy) were randomly assigned to be left untreated or received vincristine 0.2 mg/kg (VCR) (EVA Pharma B.V., Mijdrecht, Olanda) intravenously via the tail vein once/week for 4 times. The number of animals/group was based on a pre-study statistical analysis using the sensory conduction velocity as the calculation basis (20% decrease in treated vs. control rats, alpha = 0.05, beta = 80%, www.clinicalc.com). The animals were housed 2/cage in a certified animal facility under constant temperature (21°C +/− 2) and humidity (50%+/− 20) and a 12:12 h light cycle (12 AM:12 PM). Animals health status was monitored daily and body weight was recorded twice weekly to monitor general conditions and VCR dose adjustment.
At baseline and at the end of treatment the animals were tested by a blinded examiner and in random fashion with behavioral methods to assess their mechanical and thermal sensory thresholds (Dynamic and Plantar test), as previously described (Carozzi et al., 2010) . Moreover, at the end of treatment, sensory conduction studies (Sensory Nerve Action Potential [SAP] and conduction velocity) of caudal and hind limb digital nerves were obtained through an orthodromic stimulation; motor conduction studies of caudal nerve (Compound Motor Action Potential [CMAP] and conduction velocity) were also performed. In the sensory caudal nerve set up recording cathode and anode, ground electrode and stimulating anode and cathode were placed respectively at 1 cm, 2 cm, 3 cm, 5 cm 6 cm from the base of the tail. In the hind limb digital nerve set up recording cathode and anode were placed in front of the patellar bone and behind the ankle bone, respectively; stimulating anode and cathode were placed at the tip and base of the fourth toe, respectively; the ground electrode was placed in the sole. In the motor caudal nerve set up recording anode and cathode were placed in the caudal muscle at 11 and 12 cm respectively from the base of the tail; ground electrode was placed at 6 cm from the base of the tail; distal stimulation was performed placing cathode and anode respectively at 5 and 6 cm from the base of the tail and proximal stimulation was then obtained repositioning them at 1 cm and 2 cm, respectively. Filters were kept between 20 Hz and 3 KHz for sensory recordings and between 20 Hz and 2 KHz for motor recordings; sweep was kept at 0.5 msec. A Myto II EMG apparatus (EBN Neuro, Florence, Italy) and subdermal needle electrodes (Ambu Neuroline, Ambu, Ballerup, Denmark) were employed for all recordings. Nerve conduction studies were performed under deep isoflurane anesthesia and body temperature was kept constant (37°± 0.5) using a heating pad.
At the end of the treatment period, sciatic and caudal nerves were obtained for pathological examination and morphometry (Carozzi et al., 2010) ; moreover in order to include in the assessment a pathology readout already used in clinical practice, an analysis of intraepidermal nerve fiber (IENF) density was been performed on skin samples of control and VCR-treated animals collected at sacrifice (Canta et al., 2016) . On days 7, 14, 21, and 28 blood samples were withdrawn from control and treated rats and serum was obtained through centrifugation at 4°, 3500 g for 15 min. Serum was then aliquoted and stored at −80°C until NfL measurements.
Serum NfL concentration were determined using the in-house Simoa Nfl assay which has been previously described (Rohrer et al., 2016) . Samples were analyzed using one batch of reagents and animal treatment information was blinded to the examiner performing the analysis. The average repeatability of the assay was assessed by measurements of quality control samples and the coefficient of variation was 6.2% for a sample with a mean NfL concentration of 50.7 pg/ml, and 12.3% for a sample with a mean NfL concentration of 22.6 pg/ml.
Statistical analyses were carried out on raw data using GraphPad Prism4 (GraphPad, La Jolla, CA). To compare the behavioral and IENF density assessments Student's t-test was used, while NfL and neurophysiological data were analyzed using the 2-sided Mann-Whitney U test.
Results
The administration of VCR was well tolerated by the animals, with a normal weight gain (baseline: CTRL mean ± SEM 199.7 g ± 4.03 and VCR 194.3 g ± 3.48; end of treatment: CTRL mean ± SEM 218.2 g ± 5.2 and VCR 212.3 g ± 4.2); no behavioral signs of distress and no mortality were reported. The onset of VIPN was confirmed at the end of treatment by the results of the Dynamic test indicating significant mechanical allodynia (baseline: CTRL mean ± SEM 32.04 g ± 1.11 and VCR 31.72 g ± 0.75; end of treatment: CTRL mean ± SEM 30.17 g ± 0.87 and VCR 25.04 g ± 1.21; p < .01). By contrast, the change in the Plantar test results for thermal threshold induced by VCR treatment was not statistically significant (baseline: CTRL mean ± SEM 11.49 s ± 0.48 and VCR 10.81 s ± 0.294; end of treatment: CTRL 11.02 s ± 0.65; VCR 9.708 s ± 0.69; p = .19).
No significant changes were observed at the neurophysiological examination of digital nerves in VRC-treated rats. The examination of the caudal nerves evidenced at the end of treatment significant reduction in conduction velocity, SAP and CMAP potential amplitude in VCRtreated rats with respect to control animals (p < .01, Figs. 1A-F) .
At the pathologic examination performed on samples obtained at the end of VCR administration, axonopathy was evident, particularly in the caudal nerve (Figs. 1G-I ), while changes in the sciatic nerve were milder. Moreover, at the end of experiment VCR-treated animals had significant decrease of IENF density in comparison to control rats (CTRL mean ± SEM 29.77 fibers/mm ± 0.66 and VCR 21.64 fibers/mm ± 1.12; p < .0001). Serial NfL serum concentration measured in untreated and VCR-treated rats demonstrated a steady, significant increase during the course of VCR administration (Fig. 1L-O) , with a final 4-fold increase vs. controls (p < .001).
Discussion
Elevated concentrations of blood NfL have already been demonstrated to occur in several central nervous system diseases (e.g. dementia, multiple sclerosis, motor neuron disease) (Sandelius et al., 2018; Rohrer et al., 2016; Bacioglu et al., 2016; Oeckl et al., 2016) , where NfL are considered a biomarker of axonal damage. Moreover, in central nervous system diseases, NfL may also represent a possible biomarker of disease activity. In fact, in multiple sclerosis patients NfL levels correlate with treatment response and relapses (Varhaug et al., 2018) , thus adding additional relevance to their measurement. One of (caption on next page) C. Meregalli et al. Experimental Neurology 307 (2018) 129-132 the major limitations in NfL measurement was represented by insufficient standardization and methodological differences in different studies, so that their changes were inconsistent. Recently, a highly sensitive and reliable method to measure NfL concentrations was reported and tested in peripheral neuropathies, showing elevated levels and significant correlation with disease severity (Sandelius et al., 2018) . These results obtained in Charcot Marie Tooth (CMT) disease are particularly important since no effective serological disease biomarkers are available for peripheral neuropathies. Although CMT results were achieved in a cross-sectional study, the hypothesis that NfL levels might be used not only to assess the presence of peripheral nerve damage, but also to monitor the course of peripheral neuropathies deserves to be explored, particularly when monitoring is not performed by neurologists.
CIPN represents an ideal model to test this hypothesis since a) each subject can be examined before, during and after chemotherapy, so that individual baseline concentrations could be used as a very precise reference for subsequent samples; b) blood testing are routinely performed in cancer patients undergoing chemotherapy, and therefore no additional invasive procedure would be requested to obtain suitable samples, c) CIPN monitoring is a major challenge for oncologists, particularly when they are not supported by neurologists as is common in daily clinical practice, d) early detection of CIPN might prevent irreversible nerve damage, e) CIPN severity is extremely variable among patients, and the time course of NfL changes might allow for early detection of high-risk patients.
This latter point is particularly relevant since no effective treatment is currently available for CIPN once it has ensued (Cavaletti et al. 2015) , and treatment schedule modification is at present the only effective option to limit its severity and prevent the occurrence of long-term/ permanent, debilitating CIPN-related side effects (Mustafa et al. 2017) .
In the present study, serial results were obtained in a well-established animal model of repeated VCR administration inducing both sensory and motor nerves damage with the features of distal axonopathy confirmed by reduction in IENF density and relative sparing of more proximal nerves (i.e. mimicking mild-to-moderate peripheral neuropathy).
Using the same highly sensitive method used in the cross-sectional human CMT study we have demonstrated a progressive increase in serum NfL levels, that is closely correlated to pathologically-confirmed axonopathy and reflects progressive damage.
Despite additional studies including other antineoplastic drugs able to induce peripheral neurotoxicity are needed in order to verify if the results obtained in the VCR model can be reproduced in different settings, this simple monitoring approach that might be easily translated in clinical practice should be considered as a putative marker of CIPN severity in a typical oncology outpatient setting, and deserve to be tested in cancer patients treated with peripheral neurotoxic drugs. Fig. 1 . Summary of the results indicating that neurofilament light (NfL) levels are increased in the vincristine (VCR)-induced peripheral neuropathy model used in the study. Neurophysiological results obtained at the end of treatment in digital and caudal nerves in nerve Sensory Action Potential (SAP) amplitude, Compound Muscle Action Potential (CMAP) amplitude, Sensory and Motor Conduction Velocities indicate that VCR administration induced sensorimotor peripheral neuropathy (A-F, *p < .01.). Semithin sections of caudal nerves collected from a control animal (G), and proximal and distal caudal nerves from a representative VCR-treated rat (respectively, H and I) show severe distal axonopathy, with milder axonopathy in the more proximal part of the caudal nerve. NfL analyses performed after 1 (L), 2 (M) 3 (N) and 4 weeks of treatment in VCR-treated rats (O) demonstrated steady, significant increase in serum levels (boxplots report median concentrations and interquartile range, *p < .05; ***p < .001).
